US EPA

8175713 

Journal Article 

高效液相色谱法同时测定伊马替尼及主要代谢物去甲基伊马替尼的血药浓度 

Luo, XX; Huang, L; Li, TF; Xue, XC; Wang, YH; Chen, Y; Yang, CQ; Feng, WY 

2018 

Chinese Journal of New Drugs Co. Ltd. 

27 

10 

1159-1164 

Chinese 

Objective: To establish a method for determining the concentrations of imatinib and its metabolites N-desmethyl imatinib in plasma by HPLC. Methods:Blood samples were pretreated by 1 mol•L-1 NaOH using ethyl acetate n-hexane (75:25) with dasatinib as an internal standard, then concentrated in vacuum, and the reconstituted solution was detected by HPLC. The analytical column was ZORBAX SB-C18 (250 mm×4.6 mm, 5 μm), mobile phase was acetonitrile-potassium dihydrogen phosphate buffer (0.025 mol•L-1 KH2PO3, pH value was adjusted to about 3.0 by H2PO3) (27:73, V/V) at a flow rate of 1.0 mL•min-1. The detection wavelength was set at 267 nm, the temperature was kept at 35 ℃, and the injection volume was 20 μL. Results: The calibration curves had good linearity in the rang of 0.10~5.00 μg•mL-1 for imatinib and 0.010~0.05 μg•mL-1 for N-desmethyl imatinib (r=0.998 and 0.997, respectively). The limits of quantification of imatinib and N-desmethyl imatinib were 0.1 μg•mL-1 and 0.01 μg•mL-1, respectively. The extraction recoveries of low, medium and high concentration control samples were 86.02%, 87.31%, 88.21% for imatinib and 81.64%, 84.78%, 88.74% for N-desmethyl imatinib, respectively. The intra-day and inter-day RSD values were less than 15%. Conclusion: The method is simple, rapid and sensitive for drug monitoring and pharmacokinetic study on imatinib and N-desmethyl imatinib. © 2018, Chinese Journal of New Drugs Co. Ltd. All right reserved. 

HPLC; Imatinib; N-desmethyl imatinib; Therapeutic durg monitoring